Pancreatic Cancer Research

ResearcherNagoya City UniversityActive in the last 2 years

Satoru Takahashi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-8139-8158; OpenAlex author ID A5007636706. Sources: OpenAlex.

Their work

Papers
10 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
28
Papers, trials and grants by year

2017: 1 paper · 2018: 2 papers · 2019: none · 2020: 2 papers · 2021: 2 papers · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper

Papers 10

  1. The role of DPYD and the effects of DPYD suppressor luteolin combined with 5-FU in pancreatic cancer. Last author DOI 10.1002/cam4.70124↗
  2. Concomitant Pancreatic Ductal Adenocarcinoma and Type 1 Autoimmune Pancreatitis: A Potential Issue in the Diagnosis of Carcinoma by Endoscopic Ultrasound-guide… Co-author DOI 10.2169/internalmedicine.0075-22↗
  3. Class III β-Tubulin Expression Is of Value in Selecting nab -Paclitaxel and Gemcitabine as First-Line Therapy in Unresectable Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000002032↗
  4. DPYD, down-regulated by the potentially chemopreventive agent luteolin, interacts with STAT3 in pancreatic cancer. Last author DOI 10.1093/carcin/bgab017↗
  5. Cancer-Specific Targeting of Taurine-Upregulated Gene 1 Enhances the Effects of Chemotherapy in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-20-3021↗
  6. A novel sensitive detection method for DNA methylation in circulating free DNA of pancreatic cancer. Co-author DOI 10.1371/journal.pone.0233782↗
  7. Metachronous Pancreatic Ductal Adenocarcinoma with Adjacent Serous Cystadenoma that Was Preoperatively Diagnosed by EUS-FNA: A Case Report and Review of the Li… Co-author DOI 10.2169/internalmedicine.3912-19↗
  8. The absence of class III β-tubulin is predictive of a favorable response to nab-paclitaxel and gemcitabine in patients with unresectable pancreatic ductal aden… Co-author DOI 10.1016/j.humpath.2018.01.009↗
  9. Case of pancreatic metastasis from colon cancer in which cell block using the Trefle® endoscopic scraper enables differential diagnosis from pancreatic cancer. Co-author DOI 10.4251/wjgo.v10.i3.91↗
  10. Maltotriose Conjugation to a Chlorin Derivative Enhances the Antitumor Effects of Photodynamic Therapy in Peritoneal Dissemination of Pancreatic Cancer. Co-author DOI 10.1158/1535-7163.mct-16-0670↗

Closest collaborators

The 25 strongest of 28 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Akihisa Kato · 8 shared papers, 2017–2024 · strength 0.89
  2. Yoichi Matsuo · 4 shared papers, 2020–2024 · strength 0.57
  3. Itaru Naitoh · 6 shared papers, 2017–2023 · strength 0.57
  4. Michihiro Yoshida · 6 shared papers, 2017–2023 · strength 0.57
  5. Hiromi Kataoka · 5 shared papers, 2017–2023 · strength 0.52
  6. Yasuki Hori · 5 shared papers, 2017–2023 · strength 0.50
  7. Hiroyuki Kato · 3 shared papers, 2018–2024 · strength 0.39
  8. Kenta Kachi · 3 shared papers, 2020–2023 · strength 0.38
  9. Shingo Inaguma · 2 shared papers, 2021–2024 · strength 0.32
  10. Makoto Sano · 1 shared paper, 2024 · strength 0.20
  11. Hideaki Ijichi · 1 shared paper, 2024 · strength 0.20
  12. Takashi Joh · 3 shared papers, 2017–2018 · strength 0.19
  13. Tadahisa Inoue · 2 shared papers, 2018–2022 · strength 0.19
  14. Keiko Shinjo · 2 shared papers, 2020–2021 · strength 0.19
  15. Yutaka Kondo · 2 shared papers, 2020–2021 · strength 0.19
  16. Naruomi Jinno · 2 shared papers, 2018–2020 · strength 0.17
  17. Kenji Notohara · 1 shared paper, 2023 · strength 0.15
  18. Kenta Saito · 1 shared paper, 2023 · strength 0.15
  19. Hiroyuki Kato · 1 shared paper, 2022 · strength 0.12
  20. Yoshihiko Tasaki · 1 shared paper, 2021 · strength 0.10
  21. Wentao Gao · 1 shared paper, 2021 · strength 0.10
  22. Kazunori Kataoka · 1 shared paper, 2021 · strength 0.10
  23. Chenjie Qiu · 1 shared paper, 2021 · strength 0.10
  24. Kazuo Hara · 1 shared paper, 2020 · strength 0.09
  25. Keitaro Matsuo · 1 shared paper, 2020 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.